Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

  • Novo Nordisk gains full rights to Ziylo’s early-stage glucose binding molecules in a staged acquisition with a potential deal value that could exceed 800 million US dollars

  • The acquisition supports Novo Nordisk’s goal to develop glucose responsive insulins

  • Parts of the research activities in Ziylo have been spun out in a new company, Carbometrics that has entered into a research collaboration with Novo Nordisk to optimise glucose binding molecules.

  • Carbometrics has licenced rights for all non-therapeutic uses of glucose binding molecules including applications in diagnostics and glucose monitoring

BRISTOL and COPENHAGEN, 17 August 2018 ­- Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology – synthetic glucose binding molecules – for therapeutic and diagnostic applications.

Read more 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...